Related Experiment Videos
Infantile cystinosis
M Mirdehghan1, A Ahmadzadeh, M Bana-Behbahani
1Pediatric Nephrology Unit, Abuzar Children's Medical Center, University of Medical Sciences, Ahvaz, Iran. abuzarhosp-library@yahoo.com
Insights
Nephropathic cystinosis, a rare genetic disorder, affects children, causing failure to thrive and rickets. Early treatment with phosphocysteamine significantly improved clinical outcomes in affected patients.
Area of Science:
- Pediatrics
- Nephrology
- Metabolic Disorders
Background:
- Nephropathic cystinosis is a rare lysosomal storage disease.
- It leads to accumulation of cystine in various organs, causing significant morbidity in children.
- Key clinical manifestations include failure to thrive, rickets, and renal dysfunction.
Purpose of the Study:
- To report clinical findings and treatment outcomes in a cohort of patients with nephropathic cystinosis.
- To evaluate the efficacy of phosphocysteamine therapy in managing the condition.
Main Methods:
- Retrospective analysis of ten patients diagnosed with nephropathic cystinosis between 1995 and 2000.
- Assessment of clinical signs, symptoms, and laboratory parameters before and after treatment.
- Monitoring of treatment response to phosphocysteamine.
Main Results:
- All ten patients presented with failure to thrive and advanced rickets at a mean age of 12 months.
- Commonly observed symptoms included polyuria, polydipsia, pathological fractures, and deafness.
- Laboratory findings revealed glucosuria, hyposthenuria, hypocalcemia, proteinuria, and azotemia.
- Phosphocysteamine therapy resulted in marked clinical improvement across all patients.
Conclusions:
- Nephropathic cystinosis presents with severe systemic manifestations in early childhood.
- Phosphocysteamine is an effective therapeutic agent for improving clinical outcomes in nephropathic cystinosis.
- Early diagnosis and intervention are crucial for managing this rare genetic disorder.
Abstract:
Ten patients of nephropathic cystinosis were admitted during the period 1995-2000. Their mean age was 12 months. The signs of failure to thrive and advanced rickets were seen in all patients. Other features included polyuria, polydipsia, pathologic fractures and deafness. Laboratory findings included glucosuria, hyposthenuria, hypocalcemia, proteinuria and azotemia. Therapy with phosphocysteamine showed marked clinical improvement.